Request a Proposal

Impact of COVID-19 on the market access landscape

Find out how to be involved in our new syndicated study

At this time, syndicated research is more necessary than ever before. We are currently conducting a syndicated study to assess the impact of COVID-19 on biopharmaceutical market access through interviews with payers and advisors in the US, Europe, Brazil, and China: 

Sample

USA

UK

France

Germany

Italy

Spain

Brazil

China


Total

Payers / advisors

35

6

6

6

6

6

6

6

77


Our study explores both specific therapies and vaccines in development and the effects COVID-19 is expected to have on the future landscape for the life sciences industry more broadly. Including access, evidence requirements, healthcare spending and policy.

Section

Key topics

1. COVID-19 specific technologies
  1.1 Vaccines
  1.2 Drugs
  1.3 Expectations from manufacturers

  • Access routes, timelines, and the P&R process
  • Evaluation expectatsions / evidence requirements
  • Financing

2. Non COVID-19 specific technologies
  2.1 Vaccines
  2.2 Drugs
  2.3 Expectations from the industry

  • Impact on the P&R process and access timelines
  • Impact on specific therapy segments, including willingness to pay

3. Broader impact on healthcare spending

  • Budget allocation & priority setting
  • Impact on policy


 This study is relevant for:

  • Manufacturers of COVID-19 therapies and/or vaccines - to understand payer’s expectations around access routes and evidence requirements.

  • Other biopharmaceutical manufacturers - to understand the broader impact on the market access landscape.

All interviews are now complete and the results are available now. We have produced a series of three infographics outlining just some of the findings from wave one:

Vaccines Infographic Website ButtonDrugs Infographic Website ButtonCost Containment Infographic Website Button

We are also planning to run subsequent waves to track payers’ perceptions in the coming months. If this study is potentially of interest to your company and you would like to receive a more detailed overview of the study as well as further information about how we can best support you and your team, please contact us using the contact form below.

Request more information

By completing this form you agree to receive email communications, including free resources, webinars and event invitations. You can update your preferences or opt out at any time.

Brett Gardiner

Director, Market Access

Brett is a Director and heads up our specialist market access team. Brett has managed and contributed to the development of pricing and reimbursement strategies for pharmaceuticals and medical devices in all stages of the product life-cycle across all major European markets, US, Japan, Canada as well as many emerging markets. Brett has particular experience in asset valuation and value communication as well as more complex pricing research: moderation of payer and KOL dyads, focus groups, advisory boards, mock formulary committees and P&R negotiation simulations.

Brett Gardiner

Rachel Howard

Director

Rachel is currently based in London, having previously lived and worked in the US and Asia. She has considerable experience managing large-scale multi-country research projects, with particular focus on conducting research in emerging markets, and willingness to pay / pricing research. Rachel's key healthcare areas of expertise include vaccines and infectious diseases.

Rachel Howard